FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551044089> ?p ?o ?g. }

• W2551044089 endingPage "4038" @default.
• W2551044089 startingPage "4038" @default.
• W2551044089 abstract "Abstract Background. Ispinesib is a novel polycylic, nitrogen-containing heterocycle small molecule that acts by inhibition of the mitotic kinesin spindle protein (KSP) HsEg5. Pre-clinical studies demonstrate activity against both murine and human solid tumor and leukemia cell lines by inhibition of adenosine diphosphate release from KSP, causing monopolar spindle formation and programmed cell death. Methods. This was a single agent, phase I dose-escalation trial in patients with relapsed/refractory acute myeloid (AML) or lymphoid leukemia (ALL) or advanced myelodysplastic syndrome (MDS). Intravenous ispinesib was given for 3 consecutive days every 21 days. Doses were escalated from 1.5 mg/m2/day to 13.3 mg/m2/day in cohorts of 3 patients. Clinical and peripheral blood responses were monitored on at least a weekly basis and bone marrow evaluations were done every three weeks. Grade 3 or greater non-hematologic toxicities were considered dose limiting toxicities (DLT) with the exception of infectious complications, electrolyte abnormalities or self-limited gastrointestinal toxicities. Results. Thirty-six adults (14 women, 22 men) with a median age of 66.5 years (range 28–82 years) were enrolled. The median number of previous induction treatments was 3, with a range from 0 to 8. Two patients had MDS, 5 had ALL and 29 had AML. Patients received a median number of 1.5 cycles of ispinesib, with a range from 1 to 5. The maximum tolerated dose (MTD) was determined to be 10 mg/m2/day given on 3 consecutive days. DLTs related to the study drug were grade 3 transaminitis and hyperbilirubinemia, and these developed in a total of 6 patients; one at dose level 3 mg/m2/day, 2 at dose level 7.5 mg/m2/day and 3 at dose level 13.3 mg/m2/day. Five patients developed self-limited grade 3 mucositis at dose level 13.3 mg/m2/day. Three patients died on study. One died due to disease progression, and two died both due to infection and hepatic dysfunction. None of the patients had normalization of their blood counts. Three patients with very high peripheral blast counts had rapid clearing of the blasts during treatment. Two patients had late bone marrow responses with less than 5% blasts at dose level 10 mg/m2/day after cycle 2 and cycle 3, respectively; both subsequently died of infection without count recovery. An additional three patients had a decrease in bone marrow cellularity with persistence of leukemic blasts. Conclusions. The MTD of ispinesib in this patient population and on this schedule was higher than that observed in prior trials of non-hematologic malignancies (30 mg/m2versus 18 mg/m2). The toxicity profile was different with DLT of hepatic toxicity in this trial and DLT of neutropenia in the solid tumor trials. Ispinesib appeared to provide myelosuppression in some patients at higher dose levels; however, there appeared to be minimal effect on the leukemic marrow component. Even in the majority of patients with myelosuppression, the leukemic clone persisted and proliferated following treatment. Ispinesib was effective at clearing the peripheral blood of blasts in a minority of patients. Ispinesib, given as a single agent in this trial on this schedule, is not an effective anti-leukemic therapy." @default.
• W2551044089 created "2016-11-30" @default.
• W2551044089 creator A5013926915 @default.
• W2551044089 creator A5038563211 @default.
• W2551044089 creator A5042915360 @default.
• W2551044089 creator A5054435924 @default.
• W2551044089 creator A5059783665 @default.
• W2551044089 creator A5059797628 @default.
• W2551044089 creator A5068183751 @default.
• W2551044089 creator A5074672999 @default.
• W2551044089 creator A5076764341 @default.
• W2551044089 creator A5081042041 @default.
• W2551044089 date "2008-11-16" @default.
• W2551044089 modified "2023-10-07" @default.
• W2551044089 title "A Phase I Study of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Relapsed/Refractory Acute Leukemia" @default.
• W2551044089 doi "https://doi.org/10.1182/blood.v112.11.4038.4038" @default.
• W2551044089 hasPublicationYear "2008" @default.
• W2551044089 type Work @default.
• W2551044089 sameAs 2551044089 @default.
• W2551044089 citedByCount "0" @default.
• W2551044089 crossrefType "journal-article" @default.
• W2551044089 hasAuthorship W2551044089A5013926915 @default.
• W2551044089 hasAuthorship W2551044089A5038563211 @default.
• W2551044089 hasAuthorship W2551044089A5042915360 @default.
• W2551044089 hasAuthorship W2551044089A5054435924 @default.
• W2551044089 hasAuthorship W2551044089A5059783665 @default.
• W2551044089 hasAuthorship W2551044089A5059797628 @default.
• W2551044089 hasAuthorship W2551044089A5068183751 @default.
• W2551044089 hasAuthorship W2551044089A5074672999 @default.
• W2551044089 hasAuthorship W2551044089A5076764341 @default.
• W2551044089 hasAuthorship W2551044089A5081042041 @default.
• W2551044089 hasConcept C126322002 @default.
• W2551044089 hasConcept C141071460 @default.
• W2551044089 hasConcept C142424586 @default.
• W2551044089 hasConcept C2778461978 @default.
• W2551044089 hasConcept C2780007613 @default.
• W2551044089 hasConcept C71924100 @default.
• W2551044089 hasConcept C86803240 @default.
• W2551044089 hasConcept C87355193 @default.
• W2551044089 hasConcept C90924648 @default.
• W2551044089 hasConceptScore W2551044089C126322002 @default.
• W2551044089 hasConceptScore W2551044089C141071460 @default.
• W2551044089 hasConceptScore W2551044089C142424586 @default.
• W2551044089 hasConceptScore W2551044089C2778461978 @default.
• W2551044089 hasConceptScore W2551044089C2780007613 @default.
• W2551044089 hasConceptScore W2551044089C71924100 @default.
• W2551044089 hasConceptScore W2551044089C86803240 @default.
• W2551044089 hasConceptScore W2551044089C87355193 @default.
• W2551044089 hasConceptScore W2551044089C90924648 @default.
• W2551044089 hasIssue "11" @default.
• W2551044089 hasLocation W25510440891 @default.
• W2551044089 hasOpenAccess W2551044089 @default.
• W2551044089 hasPrimaryLocation W25510440891 @default.
• W2551044089 hasRelatedWork W1646480581 @default.
• W2551044089 hasRelatedWork W2059247764 @default.
• W2551044089 hasRelatedWork W2064948159 @default.
• W2551044089 hasRelatedWork W2355800873 @default.
• W2551044089 hasRelatedWork W2356481580 @default.
• W2551044089 hasRelatedWork W2377321712 @default.
• W2551044089 hasRelatedWork W2382465058 @default.
• W2551044089 hasRelatedWork W2596966782 @default.
• W2551044089 hasRelatedWork W2883338879 @default.
• W2551044089 hasRelatedWork W397034128 @default.
• W2551044089 hasVolume "112" @default.
• W2551044089 isParatext "false" @default.
• W2551044089 isRetracted "false" @default.
• W2551044089 magId "2551044089" @default.
• W2551044089 workType "article" @default.